![]() |
市场调查报告书
商品编码
1677736
偏头痛的全球市场 (~2032年):类型·治疗类型·药物类别·各地区Global Migraine Market Research Report Information by Type, By Treatment Type, By Drug Class, And by Region Market Forecast Till 2032 |
全球偏头痛市场规模预计将从 2023 年的 56.8 亿美元和 2024 年的 60 亿美元增长到 2032 年的 84.2 亿美元,预测期内的复合年增长率为 3.83%。
社会对新型药物认知的提高和全球偏头痛发生率的增加是影响该市场成长的两个主要因素。降钙素基因相关胜肽 (CGRP) 的引入预计也将推动成长。偏头痛是一种复发性剧烈头痛,伴随畏光、畏声和噁心。遗传因素在疾病的发展中扮演一定的角色。失望、紧张、焦虑、震惊和兴奋等不平衡的情绪会引发偏头痛。偏头痛发作的持续时间和强度各不相同,并且经常影响头部的一侧。偏头痛发病频率的增加、大量未满足的医疗需求、由于研发支出的增加而不断增长的药物管道以及对偏头痛和可用治疗方法的了解不断加深,也促进了该市场的成长。
区域展望
预计亚太市场在整个研究期间将见证显着的复合年增长率。随着中国和印度等新兴国家的医疗成本上升和基础设施改善,亚太市场预计将扩大。由于监管机构不断扩大举措,以合理的价格轻鬆获得偏头痛治疗选择也是推动该区域市场发展的关键因素。
欧洲占第二大市场。推动该市场成长的两个主要因素是世界范围内偏头痛问题的日益严重以及公众对新型药物认识的不断提高。此外,降钙素基因相关胜肽(CGRP)的推出也有望支持这一增长。
预计北美市场将在 2024 年至 2032 年期间以最高的复合年增长率成长。预计当地市场将受益于美国、加拿大和其他国家正在进行的大量研究和开发活动,以寻找新的治疗方案。
本报告提供全球偏头痛的市场调查,彙整市场定义和概要,市场成长的各种影响因素分析,市场规模的转变·预测,各种区分·地区/各主要国家的明细,竞争环境,主要企业简介等资讯。
Global Migraine Market Research Report Information by Type (Episodic and Chronic), By Treatment Type (Preventive, Abortive), By Drug Class (Triptans, Ergots, and Others), And by Region (North America, Europe, Asia-Pacific, And Rest of The World) Market Forecast Till 2032
In 2023, the migraine market was estimated to be worth USD 5.68 billion. The global migraine market is expected to expand at a compound annual growth rate (CAGR) of 3.83% from 2024 to 2032, from USD 6.00 billion in 2024 to USD 8.42 billion.
The two main factors propelling market expansion are the rise in migraine issues worldwide and the growing public knowledge of new medication classes.
Growing public awareness of new drug classes and a rise in migraine problems globally are two factors influencing the target market's growth. It is also anticipated that the introduction of calcitonin gene-related peptide (CGRP) will facilitate the growth of this enterprise. Migraine is a recurrent, severe headache that is accompanied by photophobia, phonophobia, and nausea. Genes play a role in the development of illness. Out-of-balance emotions, including dejection, tension, anxiety, shock, and excitement, can cause migraine headaches. Each migraine attack varies in length and intensity and often affects one side of the head. Factors include an increase in migraine frequency with substantial unmet needs, rising R&D expenditures resulting in a sizable drug pipeline, and an increase in our understanding of migraine and available treatments.
Perspectives on Market Segments
The migraine market is divided into two divisions based on type: episodic and chronic.
The migraine market is divided into two segments based on the kind of treatment: preventive and abortive.
Surgery has divided the market data into three categories: triptans, ergots, and others.
Regional Perspectives on Migraines
The analysis offers market insights by region, including Asia-Pacific, Europe, North America, and the rest of the world. Throughout the study period, a notable compound annual growth rate (CAGR) is anticipated in the Asia Pacific migraine market. As healthcare expenses rise and infrastructure in emerging countries like China and India improves, the Asia Pacific acute migraine treatment market is predicted to grow in size. The easy availability of reasonably priced migraine treatment choices backed by growing regulatory body initiatives is another significant aspect that is probably propelling the regional market. by the Brand Equity Foundation of India.
The second largest market share is held by the migraine industry in Europe. Two reasons driving the target market's growth are the rise in migraine issues worldwide and the growing public knowledge of new medicine classes. Furthermore, the launch of calcitonin gene-related peptide (CGRP) is expected to support the growth of this sector.
From 2024 to 2032, the North American migraine market is anticipated to expand at the quickest compound annual growth rate. increasing financial contributions from powerful U.S.-based parties. The local market is expected to gain from the substantial research and development activities conducted in the US, Canada, and other nations to identify novel treatment choices. According to the American Family Physician, there are approximately 441.5 million adults in the United States, of whom 6-9% are men and 18-26% are women. In 2009, the United States suffered a migraine.
Among the leading companies in the migraine market are Johnson & Johnson, Endo International Plc, GlaxoSmithKline Plc, Abbott Laboratories, Teva Pharmaceutical Industries Limited, Allergan Plc, Pfizer Inc., AstraZeneca, and Impax Laboratories.